Tissue Repair Ltd (trp) Logo

Tissue Repair Ltd (TRP)

___:___ · Healthcare

TRP Chart


TRP's Principal Activity is the tissue Repair is a clinical stage biopharmaceutical company focussed on development of wound healing technology targeting applications in the chronic wound and cosmetic procedure markets.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -78.32%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,964 of 2,413
Sector Rank 178 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies NC6 / CTQ / GLH
EPS $0.00
DPS $0.00
Book Value Per Share $0.00

Broker Consensus

TRP is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Tissue Repair Ltd (TRP) is a clinical stage biopharmaceutical company focussed on development of advanced wound healing products targeting applications in the chronic wound and cosmetic procedure aftercare markets. Tissue Repair has engaged contract manufacturers for the manufacture of its API (Glucoprime), the finished drug product (TR-987) and the finished cosmeceutical product (TR Pro+).

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Sydney NSW 2000
Website www.tissuerepair.com.au
Registry Automic Group
Auditor Pitcher Partners Sydney Partnership
Date Listed 18 Nov 2021

Upcoming Calendar (Forecasted)

Date Event
24/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Bryan William Gray Non-Executive Director Oct 2021

Mr Bryan William Gray

Non-Executive Director

Mr Gray has over 35 years of experience in Banking and Financial services in Australia and New Zealand. He spent 20 years at J.P Morgan in the Corporate and Investment Bank, the last 12 years as a Managing Director. Prior to that he held senior roles at State Street Bank and had a Chartered Accounting background in New Zealand working with Deloitte. He is currently a non-executive director of RFBI a not-for-profit business operating in the Residential Aged Care and Retirement sector. He also chairs Risk Management Committee.

Professor Craig Marshall Stamp Non-Executive Director Oct 2021

Professor Craig Marshall Stamp

Non-Executive Director

Professor Stamp has over 25 years of senior management experience in pharmaceuticals, healthcare and medical devices in Australia and Asia, previously holding senior positions at Allergan (Director Sales and Marketing) and Bausch & Lomb (Managing Director and VP Commercial Operations, Asia-Pacific). He has had public company experience having served as CEO and Managing Director at Vision Group Holdings Ltd. He was also Executive General Manager at Device Technologies between 2014 and 2020 and is Chair of the School of Optometry and Vision Science (SOVS) Visiting Committee and is an Adjunct Associate Professor of the SOVS, Faculty of Medicine and Health, UNSW. He was a former Director of the Medical Technology Association of Australia (MTAA) and was Chair of the MTAA Finance Committee. He is also a member of Risk Management Committee.

Mr Robert (Max) Maxwell Johnston Non-Executive Director Oct 2021

Mr Robert (Max) Maxwell Johnston

Non-Executive Director

Mr Johnston held the position of President and Chief Executive Officer (CEO) of Johnson & Johnson Pacific for 11 years. Prior to joining Johnson & Johnson, his career also included senior roles with Diageo and Unilever in Europe. He has also held several industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Skills Management Institute. He is currently Non-Executive Chairperson of AusCann Group Holdings Limited and a Non-Executive Director of Medical Developments International Ltd and BARD1 Life Sciences Ltd. Former board roles include Non-Executive Director of PolyNovo Ltd and Enero Group Limited, as well as Non-Executive Chairperson of Probiotec. He is also a member of Risk Management Committee.

Mr Jack Theseus Lowenstein Non-Executive Chairman,Non-Executive Director Aug 2021

Mr Jack Theseus Lowenstein

Non-Executive Chairman,Non-Executive Director

Mr Lowenstein has over 25 years of senior management experience in financial services and was involved in developing Australian ESG investment, first at Hunter Hall Investment Management from 1997 to 2011, and then from 2012 to 2019 at Morphic Asset Management. He remains a non-executive director at Morphic. He was also a co-founder of Fiji's first investment bank, Kontiki Capital which he chaired from its inception in 1998 to 2017, and remains a director of Kinetic Growth Fund, which is listed on the South Pacific Stock Exchange. He has been a director of several Australian ASX listed public companies, including Hunter Hall International, Hunter Hall Global Value, Kresta Holdings, Reinsurance Australia and Calliden Group. He is currently a director of Morphic Ethical Equities and Fiji Kava. He is also a member of Risk Management Committee.

Mr Tony Charara Co-Founder,Executive Director May 2012

Mr Tony Charara

Co-Founder,Executive Director

Mr Charara is an investment banker by background and has experience across early-stage venture assets and in advising technology companies at ANZ Investment Bank, Ord Minnett Securities and JPMorgan in their respective investment banking teams. He is also a co-founder of Mable Technologies, an online marketplace and health technology platform operating in the aged care and disability sectors.

Mr Alistair Gregory McKeough Company Secretary N/A

Director Transactions

TRP directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
01/03/22 Bryan Gray Buy +55,719 $0.435 $24,220 On-market trade
22/11/21 Tony Charara Buy +73,076 $0.676 $49,364 On-market trade
19/11/21 Robert (Max) Johnston Buy +70,000 $0.705 $49,350 On-market trade
18/11/21 Jack Lowenstein Buy +22,000 $0.721 $15,867 On-market trade

Director Interests

The current holdings of TRP directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Bryan Gray 01/03/2022 68,759 N/A 366,060 N/A
Tony Charara 22/11/2021 73,076 4,822,260 13,640,000 N/A
Robert (Max) Johnston 19/11/2021 26,080 70,000 366,060 N/A
Jack Lowenstein 18/11/2021 48,080 N/A 366,060 N/A
Craig Stamp 07/10/2021 26,080 N/A 366,060 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Nov 16, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Selene Holdings Ltd 5,955,980 9.85%
Spark Capital Pty Limited 4,822,260 7.98%
Creight Investments Pty Ltd <987 Trust A/C> 3,031,720 5.01%
CS Third Nominees Pty Limited <Hsbc Cust Nom Au Ltd 13 A/C> 2,434,783 4.03%
Welas Pty Ltd <Wales Family Trust A/C> 2,317,580 3.83%
Washington H Soul Pattinson And Company Limited 2,038,043 3.37%
Mark Deacon-Shaw 2,035,160 3.37%
Bannaby Investments Pty Limited 1,690,580 2.80%
Moore Family Nominee Pty Limited 1,217,400 2.01%
HSBC Custody Nominees (Australia) Limited 1,070,274 1.77%
Gidley Baird Holdings Pty Ltd 1,055,440 1.75%
Creight Investments Pty Ltd <Scutt Retirement Fund A/C> 990,540 1.64%
Warwick Nettle Pty Limited <Warwick Nettle Superannuationfund A/C> 967,040 1.60%
Mapd Nominees Pty Ltd 849,722 1.41%
Phytose Corporation Limited <Boundaryone S/F A/C> 793,940 1.31%
Terrence Joseph Caplice 730,440 1.21%
Citicorp Nominees Pty Limited 652,174 1.08%
UBS Nominees Pty Ltd 634,784 1.05%
Cinderella Management Company Pty Ltd <The Cinderella Unit A/C> 608,694 1.01%
RG Roden Pty Limited 608,680 1.01%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 6 206 210 377 68 867

Substantial Shareholders

No Substantial Shareholders for TRP in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
18-11-21 Selene Holdings Ltd 5,955,980 -- 9.85
18-11-21 Tony Charara 4,895,336 -- 8.10

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
TRP Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.